Treatment of attacks with plasma-derived C1-inhibitor concentrate in pediatric hereditary angioedema patients - 27/02/13
This work was supported by grant no. OTKA-NKTH 100886 (to H.F.). |
|
Disclosure of potential conflict of interest: H. Farkas has consultancy arrangements with Shire Human Genetic Therapies, Inc, Pharming, Viropharma, and CSL Behring; has received one or more payments for lecturing or is on the speakers’ bureau for Shire Human Genetic Therapies, Inc; and has received one or more payments for travel/accommodations/meeting expenses from Shire Human Genetic Therapies, Inc, Pharming, Viropharma, and CSL Behring. D. Csuka has received one or more payments for travel/accommodations/meeting expenses from Shire Human Genetic Therapies, Inc, Viropharma, and CSL Behring. L. Varga has received one or more payments for travel/accommodations/meeting expenses from Shire Human Genetic Therapies, Inc, Viropharma, and CSL Behring. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 131 - N° 3
P. 909 - mars 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?